Bank of Nova Scotia
IMGN

Bank of Nova Scotia’s Immunogen Inc IMGN Stock Holding History

Bank of Nova Scotia’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-83,100
Closed -$591K – 1002
2017
Q2 		$591K Buy
+83,100
New +$380K ﹤0.01% 839

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of Nova Scotia's IMGN Position: Q3 2017 in Review

Bank of Nova Scotia sold out of Immunogen Inc (IMGN) in Q3 2017, closing a stake of 83,100 shares — an estimated $591K sold.

Bank of Nova Scotia first reported a position in IMGN in Q2 2017 and held it in 1 quarter. The position peaked at $591K in Q2 2017. 180 funds tracked by Wall St. Rank hold IMGN as of Q3 2017.

  • Bank of Nova Scotia reported no remaining Immunogen Inc position as of Q3 2017 after selling out during the quarter.
  • Bank of Nova Scotia sold 83,100 Immunogen Inc shares in Q3 2017, an estimated $591K.
  • Bank of Nova Scotia first reported a position in Immunogen Inc in Q2 2017 and held it in 1 quarter.
  • Bank of Nova Scotia's Immunogen Inc position peaked at $591K in Q2 2017.
  • 180 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2017.

Based on Bank of Nova Scotia's 13F filing for Q3 2017, filed 14 Nov 2017.